Sayre Therapeutics raises $8 mn from Accel Partners & Aarin Capital

Sayre Therapeutics, a super-specialty pharmaceutical company with a portfolio of Oncology, Interventional Oncology and Immunology drugs, drug delivery devices and next-generation diagnostics, has raised $8 mn USD across two rounds of funding from Accel Partners and Aarin Capital. The company has also raised $1Mn USD in venture-debt from InnoVen Capital.
 
The Bengaluru-based Sayre Therapeutics plans to use the funds for team expansion in India, geographical footprint in other South Asian countries, and invest in clinical trials for their novel in-licensed assets.
 
According to Shukrit Chimote, Chief Executive Officer, Sayre, the follow-on investment from the venture capitalists were based on the early traction seen in building a product pipeline through partnerships with global and domestic partners, a sales footprint in India and a strong team to capitalise on a USD 650MM market for Oncology and Immunology segments in the region”.

“We seek to fill the gaps in early cancer diagnosis and treatment by licensing in novel drugs, devices and diagnostics to the country at an affordable cost, and a significant discount to the global prices. We will continue to expand the scope of medical care by bringing in these advanced medical technologies and drugs, and thereby provide more options to the physicians and patients in the subcontinent,” said Vandana Subramanian, Chief Business Officer, Sayre. 

 “Our medical science liaisons and key account managers continue to partner doctors and educate patients on new solutions in the fast-evolving field of cancer,” said Praveen Bose, SVP & Head, Sales & Marketing, Sayre.

Sayre is South Asia’s only integrated platform for disease management backed by a unique distribution and commercialization model for novel and / or differentiated drugs, molecular diagnostics and drug-delivery devices in the super-specialty areas of Oncology, Interventional Oncology and Immunology. It was set up in 2015 backed by leading global venture capital firms – Accel Partners & Aarin Capital. The team has years of global executive experience in leading pharmaceuticals, medical diagnostics & devices companies. The company is creating a portfolio of differentiated global assets in emerging markets, including India, Sri Lanka, Bangladesh and Nepal, which are witnessing high growth for pharmaceutical products. Sayre has a geographically focused strategy, strong financial backing and a solid understanding of the clinician networks and the regulatory landscape in the region.
Source:http://www.pharmabiz.com/NewsDetails.aspx?aid=104124&sid=2

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more